Technical analysis of Xencor, Inc. (XNCR): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders.
Price Performance
| 1 month | +19.96% |
| 3 months | +48.39% |
| Year-to-date | +95.89% |
| 1 year | +104.43% |
| 3 years | +74.06% |
| 5 years | -24.19% |
| 10 years | +40.86% |
52-Week Range
| 52-week High | $33.60 |
| 52-week Low | $10.38 |
| Avg Volume (90d) | 1.4M |
Technical Indicators
| SMA 50 | $25.65 |
| SMA 200 | $16.80 |
| Beta | 0.99 |
| 30-day Volatility (annualised) | 63.3% |
| Price vs SMA 50 | +16.9% |
| Price vs SMA 200 | +78.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $15.31 | |
| 2026-01 | $12.09 | -21.0% |
| 2026-02 | $12.77 | +5.6% |
| 2026-03 | $12.06 | -5.6% |
| 2026-04 | $11.93 | -1.1% |
| 2026-05 | $11.88 | -0.4% |
| 2026-06 | $16.10 | +35.5% |
| 2026-07 | $20.21 | +25.5% |
| 2026-07 | $20.21 | +0.0% |
| 2026-08 | $27.27 | +34.9% |
| 2026-09 | $24.95 | -8.5% |
| 2026-10 | $29.99 | +20.2% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-04 | $-0.33 | $63M |
| 2026-08-05 | $-0.80 | $19M |
| 2026-05-06 | $-0.65 | $28M |
| 2026-02-25 | $-0.64 | $30M |
| 2025-11-05 | $-0.72 | $30M |
| 2025-08-06 | $-0.78 | $24M |
| 2025-05-07 | $-0.63 | $22M |
Price
| Price | $29.99 (closing price, October 28, 2026) |
| Market Cap | $2.2B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 5.38 |
| EV / EBITDA | -18.21 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.13 |
| Current Ratio | 6.39 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 1.73 |